AEZS Aeterna Zentaris Inc. Stock Quote

AEZS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.15	Insider Own	0.60%	Shs Outstand	62.84M	Perf Week	2.30%
Market Cap	117.58M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	62.62M	Perf Month	-21.08%
Income	-5.10M	PEG	-	EPS next Q	-	Inst Own	21.40%	Short Float	12.34%	Perf Quarter	21.11%
Sales	3.70M	P/S	31.78	EPS this Y	63.90%	Inst Trans	0.82%	Short Ratio	0.41	Perf Half Y	160.94%
Book/sh	0.21	P/B	4.43	EPS next Y	-	ROA	-19.20%	Target Price	-	Perf Year	19.40%
Cash/sh	0.19	P/C	4.84	EPS next 5Y	-	ROE	-66.10%	52W Range	0.29 - 3.62	Perf YTD	118.87%
Dividend	-	P/FCF	-	EPS past 5Y	63.10%	ROI	-45.90%	52W High	-73.48%	Beta	1.86
Dividend %	-	Quick Ratio	5.60	Sales past 5Y	46.30%	Gross Margin	36.60%	52W Low	231.00%	ATR	0.12
Employees	11	Current Ratio	5.60	Sales Q/Q	13044.40%	Oper. Margin	-	RSI (14)	44.67	Volatility	10.95% 10.31%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	58.50%	Profit Margin	-	Rel Volume	0.11	Prev Close	0.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	18.96M	Price	0.96
Recom	-	SMA20	-7.45%	SMA50	-19.73%	SMA200	44.57%	Volume	326,845	Change	3.07%

Jul-19-17

Reiterated

Maxim Group

Buy

$2 → $4

May-10-17

Reiterated

H.C. Wainwright

Buy

$7.50 → $3

May-01-17

Reiterated

Maxim Group

Buy

$11 → $2

Jan-17-17

Reiterated

Maxim Group

Buy

$7 → $10

Dec-02-15

Reiterated

H.C. Wainwright

Buy

$11 → $12

Nov-24-15

Reiterated

H.C. Wainwright

Buy

$0.11 → $11

Nov-23-15

Reiterated

Maxim Group

Buy

$200 → $11

Apr-14-15

Upgrade

H.C. Wainwright

Neutral → Buy

$1.25

Nov-06-14

Downgrade

H.C. Wainwright

Buy → Neutral

Jul-17-14

Initiated

H.C. Wainwright

Buy

Jan-03-13

Upgrade

MLV & Co

Hold → Buy

$5.50

Oct-09-12

Initiated

Maxim Group

Buy

Apr-02-12

Downgrade

MLV & Co

Buy → Hold

Jun-07-11

Initiated

Oppenheimer

Outperform

$5.50

Apr-27-11

Reiterated

Canaccord Genuity

Speculative Buy

$2.75 → $4

Nov-29-10

Initiated

MLV Capital

Buy

$5.50

Feb-05-09

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Jun-03-08

Reiterated

Canaccord Adams

Buy

$3.20 → $2.65

Apr-14-08

Reiterated

Canaccord Adams

Buy

$4.50 → $3.20

Oct-03-07

Reiterated

Rodman & Renshaw

Mkt Outperform

$8 → $6

Mar-30-21 02:23AM	Should Aeterna Zentaris (TSE:AEZS) Be Disappointed With Their 100% Profit? Simply Wall St.
Mar-25-21 08:05AM	Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire +6.36%
Mar-22-21 04:05PM	Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
Mar-15-21 09:11AM	Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate Benzinga +27.97%
08:05AM	Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19 GlobeNewswire
Mar-11-21 08:05AM	Aeterna Zentaris Continues to Demonstrate Pipeline Expansion Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism GlobeNewswire +22.77%
Feb-24-21 08:05AM	Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Feb-19-21 01:25PM	Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares GlobeNewswire +5.71%
Feb-16-21 10:00PM	Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million GlobeNewswire
05:19PM	Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares GlobeNewswire
Feb-02-21 07:30AM	Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg GlobeNewswire +42.86%
Jan-28-21 08:05AM	Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics GlobeNewswire
Jan-26-21 04:05PM	Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule GlobeNewswire
Jan-15-21 08:05AM	Aeterna Zentaris to Present at NobleCon17 GlobeNewswire -5.88%
Jan-05-21 08:05AM	Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Dec-29-20 11:46PM	We Think Aeterna Zentaris (TSE:AEZS) Needs To Drive Business Growth Carefully Simply Wall St. -6.00%
Dec-07-20 08:05AM	Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin GlobeNewswire -10.94%
Nov-16-20 08:05AM	Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin GlobeNewswire
Nov-06-20 08:35AM	Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-09-20 08:00AM	The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc. - AEZS PR Newswire
Sep-16-20 08:05AM	Aeterna Zentaris Provides Corporate Update GlobeNewswire
Sep-09-20 08:00AM	Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
07:23AM	The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment Benzinga
Sep-08-20 08:05AM	Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology GlobeNewswire
Aug-06-20 08:35AM	Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-05-20 05:45PM	Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market GlobeNewswire
Aug-03-20 09:00AM	AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET GlobeNewswire -8.63%
Jul-31-20 07:35AM	Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications GlobeNewswire
Jul-30-20 07:35AM	AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY GlobeNewswire
Jul-29-20 07:05AM	Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing GlobeNewswire
Jul-07-20 04:05PM	AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING GlobeNewswire +24.53%
Jul-03-20 07:12AM	Is Aeterna Zentaris (TSE:AEZS) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Jul-01-20 10:10PM	AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING GlobeNewswire -32.67%
Jun-25-20 08:00AM	AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY GlobeNewswire +5.58%
Jun-08-20 08:05AM	Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement GlobeNewswire
Jun-04-20 04:05PM	Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements GlobeNewswire
May-15-20 04:45PM	Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders GlobeNewswire
May-08-20 09:00AM	Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders GlobeNewswire
May-06-20 08:05AM	Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results GlobeNewswire +31.54%
May-03-20 07:30PM	One Biotech Stock For 2020 Oilprice.com
Apr-30-20 03:08PM	Gilead's remdesivir will set new standard of care for coronavirus treatment: Fauci Yahoo Finance Video
Apr-15-20 04:06PM	Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing GlobeNewswire
09:15AM	Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit GlobeNewswire
Apr-07-20 01:00PM	AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN GlobeNewswire
Apr-06-20 09:00AM	AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN GlobeNewswire +55.72%
Apr-03-20 10:36AM	We'll weather the coronavirus storm well and come out very strong: Cigna Services President Yahoo Finance Video
Mar-30-20 05:00PM	AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE GlobeNewswire -8.51%
Mar-12-20 08:00AM	AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT GlobeNewswire -17.74%
Feb-21-20 02:00PM	Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market GlobeNewswire
Feb-20-20 07:06AM	The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga -25.00%
Feb-19-20 07:00PM	Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market GlobeNewswire
Feb-12-20 08:05AM	Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference GlobeNewswire
Jan-28-20 08:00AM	Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin GlobeNewswire
Jan-27-20 08:35AM	Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing GlobeNewswire
Jan-09-20 08:39AM	The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results Benzinga -9.02%
Jan-08-20 04:01PM	Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement GlobeNewswire +14.42%
Dec-30-19 06:38AM	Companies Like Aeterna Zentaris (TSE:AEZS) Can Be Considered Quite Risky Simply Wall St. +15.20%
Dec-20-19 05:45PM	Hedge Funds Have Never Been This Bullish On AEterna Zentaris Inc. (AEZS) Insider Monkey
Dec-18-19 09:00AM	Aeterna Zentaris Announces Publication of GHD Management Guidelines GlobeNewswire
Dec-16-19 09:00AM	Aeterna Zentaris Announces 2020 Director Changes GlobeNewswire
Nov-07-19 06:28PM	Aeterna Zentaris Reports Third Quarter 2019 Financial and Operating Results GlobeNewswire
Nov-05-19 07:56AM	Top Ranked Value Stocks to Buy for November 5th Zacks +7.46%
Oct-29-19 10:33AM	Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-08-19 09:00AM	What Makes Aeterna Zentaris (AEZS) a New Buy Stock Zacks
Oct-04-19 04:59PM	Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer GlobeNewswire
Sep-26-19 06:34AM	Can We See Significant Institutional Ownership On The Aeterna Zentaris Inc. (TSE:AEZS) Share Register? Simply Wall St. -5.13%
Sep-24-19 04:01PM	Aeterna Zentaris Announces Closing of Approximately $5.0 Million Registered Direct Offering GlobeNewswire
Sep-20-19 11:00AM	Aeterna Zentaris Announces Pricing of Approximately $5.0 Million Registered Direct Offering GlobeNewswire -22.42%
Aug-20-19 11:16PM	Aeterna Zentaris Announces Director Change GlobeNewswire
Aug-13-19 05:45PM	Aeterna Zentaris (AEZS) Beats Q2 Earnings Estimates Zacks +11.16%
04:15PM	Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results GlobeNewswire
Aug-01-19 10:33AM	Will Aeterna Zentaris (AEZS) Report Negative Q2 Earnings? What You Should Know Zacks -5.20%
Jul-01-19 10:30AM	Options Traders Expect Huge Moves in Aeterna Zentaris (AEZS) Stock Zacks
Jun-06-19 02:06PM	Aeterna Zentaris Provides Corporate Update GlobeNewswire -13.38%
May-08-19 06:04PM	Aeterna Zentaris Announces Results of Annual and Special Shareholders Meeting GlobeNewswire -11.32%
May-07-19 07:25PM	Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:22PM	Aeterna Zentaris: 1Q Earnings Snapshot Associated Press
05:12PM	Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results GlobeNewswire
May-02-19 10:02AM	What's in the Cards for AEterna (AEZS) This Earnings Season? Zacks
Apr-29-19 10:31AM	Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for Zacks
Mar-26-19 07:50PM	Aeterna Zentaris: 4Q Earnings Snapshot Associated Press
05:22PM	Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results GlobeNewswire
Mar-19-19 08:00AM	Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019 GlobeNewswire +5.50%
Mar-18-19 11:18AM	Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade Zacks
Mar-13-19 07:27AM	The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie Benzinga +8.40%
Mar-12-19 04:32PM	Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor GlobeNewswire
Mar-04-19 08:58AM	What's in the Cards for Aeterna (AEZS) This Earnings Season? Zacks -5.50%
Feb-27-19 09:57AM	The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris Zacks
Feb-26-19 08:55AM	4 Drug Stocks to Buy Despite Price Hearing Woes Zacks
Feb-14-19 10:45AM	The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks
Feb-13-19 08:36AM	5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Jan-29-19 09:30AM	Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year? Zacks
08:48AM	Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options Zacks
Jan-16-19 09:03AM	Aeterna Zentaris Receives European Marketing Clearance for Macimorelin GlobeNewswire -10.00%
Jan-09-19 09:50AM	Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan Zacks
Jan-07-19 09:30AM	Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year? Zacks
Dec-24-18 05:50PM	Aeterna Zentaris (AEZS) Stock Moves -1.16%: What You Should Know Zacks
Dec-21-18 05:04PM	Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore GlobeNewswire -5.82%
Dec-20-18 09:30AM	Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year? Zacks
Dec-17-18 05:50PM	Aeterna Zentaris (AEZS) Gains As Market Dips: What You Should Know Zacks

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience